收费全文 | 522604篇 |
免费 | 34389篇 |
国内免费 | 638篇 |
医药卫生 | 557631篇 |
2018年 | 5226篇 |
2016年 | 4312篇 |
2015年 | 4810篇 |
2014年 | 6510篇 |
2013年 | 10129篇 |
2012年 | 13823篇 |
2011年 | 15188篇 |
2010年 | 8819篇 |
2009年 | 8255篇 |
2008年 | 14479篇 |
2007年 | 15539篇 |
2006年 | 15726篇 |
2005年 | 15214篇 |
2004年 | 14833篇 |
2003年 | 14047篇 |
2002年 | 13858篇 |
2001年 | 24149篇 |
2000年 | 25114篇 |
1999年 | 20556篇 |
1998年 | 5278篇 |
1997年 | 4516篇 |
1996年 | 4839篇 |
1995年 | 4683篇 |
1994年 | 4371篇 |
1992年 | 15755篇 |
1991年 | 16345篇 |
1990年 | 16459篇 |
1989年 | 15823篇 |
1988年 | 14608篇 |
1987年 | 14459篇 |
1986年 | 13642篇 |
1985年 | 13015篇 |
1984年 | 9661篇 |
1983年 | 8281篇 |
1982年 | 4592篇 |
1981年 | 4244篇 |
1979年 | 9434篇 |
1978年 | 6850篇 |
1977年 | 5775篇 |
1976年 | 5598篇 |
1975年 | 6378篇 |
1974年 | 7630篇 |
1973年 | 7129篇 |
1972年 | 6954篇 |
1971年 | 6680篇 |
1970年 | 6178篇 |
1969年 | 5892篇 |
1968年 | 5560篇 |
1967年 | 5011篇 |
1966年 | 4458篇 |
Vaccination prevents severe morbidity and mortality from COVID-19 in the general population. The immunogenicity and efficacy of SARS-CoV-2 vaccines in patients with antibody deficiency is poorly understood.
ObjectivesCOVID-19 in patients with antibody deficiency (COV-AD) is a multi-site UK study that aims to determine the immune response to SARS-CoV-2 infection and vaccination in patients with primary or secondary antibody deficiency, a population that suffers from severe and recurrent infection and does not respond well to vaccination.
MethodsIndividuals on immunoglobulin replacement therapy or with an IgG less than 4 g/L receiving antibiotic prophylaxis were recruited from April 2021. Serological and cellular responses were determined using ELISA, live-virus neutralisation and interferon gamma release assays. SARS-CoV-2 infection and clearance were determined by PCR from serial nasopharyngeal swabs.
ResultsA total of 5.6% (n?=?320) of the cohort reported prior SARS-CoV-2 infection, but only 0.3% remained PCR positive on study entry. Seropositivity, following two doses of SARS-CoV-2 vaccination, was 54.8% (n?=?168) compared with 100% of healthy controls (n?=?205). The magnitude of the antibody response and its neutralising capacity were both significantly reduced compared to controls. Participants vaccinated with the Pfizer/BioNTech vaccine were more likely to be seropositive (65.7% vs. 48.0%, p?=?0.03) and have higher antibody levels compared with the AstraZeneca vaccine (IgGAM ratio 3.73 vs. 2.39, p?=?0.0003). T cell responses post vaccination was demonstrable in 46.2% of participants and were associated with better antibody responses but there was no difference between the two vaccines. Eleven vaccine-breakthrough infections have occurred to date, 10 of them in recipients of the AstraZeneca vaccine.
ConclusionSARS-CoV-2 vaccines demonstrate reduced immunogenicity in patients with antibody deficiency with evidence of vaccine breakthrough infection.
相似文献